Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

March 31, 2025

Primary Completion Date

June 30, 2028

Study Completion Date

December 31, 2028

Conditions

Relapsed or Refractory B-cell Malignancies

Interventions

DRUG

EXS73565

EXS73565 oral administration

Trial Locations (3)

RECRUITING

Hospital Fundación Jiménez Diaz, Madrid

RECRUITING

Hospital Universitario HM Sanchinarro, Madrid

RECRUITING

University Hospitals Plymouth NHS Trust, Plymouth

All Listed Sponsors

lead

Exscientia AI Limited

INDUSTRY